| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_953ff33396ac95780be2489d7a6cbcd4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_acb995eb22f9306adb4ab9027d8fda8f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0cf49a0d6f48f349b456177bc78db75c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_02040aa7fee4a12a76ed46d38cf5d439 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2800-782 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61Q19-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-1024
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-64 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-06 |
| filingDate |
2008-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2011-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c04252b4a16987f6470419c4af5cd2a0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dfc342026039c42bdee08328b428a96a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2937b2bdf276e87accd4ce45bb60d570 |
| publicationDate |
2011-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8071555-B2 |
| titleOfInvention |
Protective skin care peptides |
| abstract |
The disclosed invention provides tetrapeptides with the amino acid sequence proline-glutamine-glutamate-X (P-Q-E-X), where X can be either lysine (K) or isoleucine (I). These tetrapeptides inhibit ultraviolet light (UV)-induced expression of the pro-inflammatory cytokine interleukin-6 (IL-6) by skin epithelial cells and fibroblasts. Furthermore, the tetrapeptides repress the upregulation of matrix metalloproteinase-1 (MMP-1) by skin fibroblasts induced by either direct exposure to UV rays or treatment with media conditioned by UV-treated keratinocytes. The small size and bio-activity of the tetrapeptides render them suitable for use in therapies directed to inflammatory skin disorders and as active ingredients in skin care products. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-3123193-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9351911-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9636292-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9913785-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022248670-A1 |
| priorityDate |
2007-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |